Therapeutic indications
Survanta is indicated for treatment of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in new born premature infants with a birth weight of 700g or greater and who are intubated and are receiving mechanical ventilation.Survanta is also indicated for the prophylactic treatment of premature infants <32 weeks gestational age at risk of developing RDS.
Key points:
Pharmacodynamic properties
Pharmacokinetic properties
Preclinical safety data
There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.
Special precautions for disposal and another handling
SALVAVIDAS PHARMACEUTICAL PVT. LTD.
All Rights Reserved.(Terms of Use) Developed and Managed by Infocom Network Private Limited. |